Iodine-131 in breast milk following therapy for thyroid carcinoma.
This study evaluates breast milk secretion of 131I following therapeutic administration of 4000 MBq of 131I-iodide during lactation.


METHODS
Breast milk 131I activity concentration was measured over a 32-day period. Dosimetry calculations were undertaken to estimate the period for discontinuation of breast feeding and the equivalent dose to the breasts.


RESULTS
To achieve an infant effective dose < 1 mSv and an infant thyroid dose < 10 mSv, breast feeding would need to be discontinued for at least 52 days. The estimated equivalent dose to the breasts was 1.6 Gy.


CONCLUSIONS
It is suggested that 131I-iodide administration is not undertaken during lactation and that breast feeding is discontinued several days prior to administration.
Department of Nuclear Medicine, Royal Perth Hospital, Australia.
P S
PS
Robinson
P
P
Barker
A
A
Campbell
P
P
Henson
I
I
Surveyor
P R
PR
Young
D018263:Adenocarcinoma, Follicular / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D001940:Breast / Q000528:radiation effects; D001942:Breast Feeding; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007223:Infant; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008895:Milk, Human / Q000737:chemistry*; D011829:Radiation Dosage; D011879:Radiotherapy Dosage; D012307:Risk Factors; D012974:Sodium Iodide / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D013965:Thyroidectomy; D013997:Time Factors
D007457:Iodine Radioisotopes; D012974:Sodium Iodide